论文部分内容阅读
1983～1988年,我们使用盐酸一叶萩碱并以加兰他敏为对照药物,随机对临床诊断为脊髓灰质炎的住院患儿124例,其中经病原学证实者54例,未经病原学证实者70例,进行了疗效观察。在经病原学证实的54例脊灰炎患儿中,一叶萩碱治疗28例,有效者27例,有效率为96.43%加兰他敏治疗28冽,有效者21例,有效率为80.77%。从两药分别治疗中、重型病例基本治愈数和显著好转数两者相加之和来看,一叶萩碱组比例为61.54%(16/28),加兰他敏组比例为33.33%(8/24),经检验有显著性差异(X~2=2.98,P<0.05),提示盐酸一叶萩碱对脊灰炎中、重型病例的疗效明显优于加兰他敏,应作为治疗脊灰炎的首选药物,且显示坚持长疗程的治疗效果更好,长期使用无全身及局部毒付作用。
From 1983 to 1988, we used 124% of hospitalized patients diagnosed with poliomyelitis randomly as the control drug, montmorine hydrochloride and galantamine, of which 54 were confirmed by etiology, without etiology Confirmed in 70 cases, the efficacy of the observation. Among the 54 cases of poliovirus confirmed by etiology, 28 cases were treated with monkshoodine, 27 cases were effective, the effective rate was 96.43%, 28 cases were treated with galanthamine, 21 cases were effective, the effective rate was 80.77 %. In terms of the sum of the basic cure rate and the significant improvement rate of the two kinds of drugs in the treatment of middle and heavy cases, the ratio of the single-leaf alkali group was 61.54% (16/28), the galanthamine group was 33.33% 8/24). There was significant difference (X ~ 2 = 2.98, P <0.05), which indicated that the therapeutic effect of monosodium hydroxide hydrochloride was better than that of galantamine in moderate and severe cases of poliomyelitis. Poliomyelitis drug of choice, and shows that the treatment of long-term treatment adherence is better, long-term use without systemic and local poisoning effect.